👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Judge rules J&J owes Auris investors $1 billion related to 2019 robotics deal

Published 09/04/2024, 11:00 AM
Updated 09/05/2024, 05:48 AM
© Reuters. FILE PHOTO: The logo of Johnson & Johnson is seen on the top of a Brussels' office of the company in Diegem, Belgium September 21, 2023.  REUTERS/Yves Herman/File Photo
JNJ
-

By Tom Hals

WILMINGTON, Delaware (Reuters) -Johnson & Johnson owes shareholders of Auris Health $1 billion in damages for breaching a 2019 agreement to acquire the private developer of robotics, a Delaware judge ruled on Wednesday.

Vice Chancellor Lori Will of the Court of Chancery found after a two-week trial that J&J (NYSE:JNJ) had breached a merger agreement and failed to support the acquired iPlatform technology, which would have led to increased payments to Auris shareholders.

J&J had paid $3.4 billion up front in cash, but also committed to paying up to an additional $2.35 billion to Auris shareholders if various milestones were met with the acquired technology.

"J&J’s promise to Auris was broken almost immediately after closing," Will said in her 145-page ruling.

The New Jersey-based healthcare conglomerate also acquired Auris' Monarch robotic platform and the pair were developed to diagnose and treat lung cancer.

The judge said that rather than dedicating resources to the iPlatform device so it could achieve regulatory milestones and deliver additional payments to Auris shareholders, J&J forced it to compete with its own Verb device.

"The iPlatform robot effectively became a parts shop for Verb," Will wrote.

J&J said it disagreed with the ruling and was considering an appeal.

“Fundamentally, the court viewed our commercially reasonable contract as imposing a commercially unreasonable obligation," the company said. J&J also said the ruling had no bearing on its current robotics program.

J&J blamed the missed milestone goals on technical problems with the Auris devices, according to Will's ruling. The company also has asserted the merger agreement allowed it to use Auris' products in any way that advanced J&J's overall robotics program, a claim Will disputed in her opinion.

© Reuters. FILE PHOTO: A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023.  REUTERS/Brendan McDermid/File Photo

Shares of J&J were little changed at $167.46 in midday trading.

Auris investors included founder Dr. Fred Moll, Lux Capital Management, Mithril Capital Management, which was the largest shareholder, and Highland Capital Management, according to court records. A unit of J&J also invested in Auris.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.